Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data

BMS dumps $100M Orum degrader-antibody conjugate after glimpsing phase 1 data

  • September 18, 2026

Bristol Myers Squibb has axed the degrader-antibody conjugate it bought from Orum Therapeutics for $100 million, walking away from the asset after seeing phase 1 data.

Leave A Comment

Fields (*) Mark are Required